Section 7.1 Laboratory

Laboratory Report #19

Date

Collection Date: June 6, 2022
Report Date: June 7, 2022

Laboratory

Labcorp

Ordering Physician

Dr. Rihab Kheir

Report Type

Inflammation Monitoring Evaluation

Laboratory testing included:

Erythrocyte Sedimentation Rate (ESR)
C-Reactive Protein (CRP)

Original Report

PDF: Labcorp – June 6, 2022

One-Page Summary

Purpose of Testing

This laboratory evaluation was performed as part of ongoing rheumatology follow-up to monitor for recurrence of systemic inflammation after the severe inflammatory illness of 2021. The focus of this study was to measure the two primary inflammatory markers—ESR and CRP—to determine whether remission had been maintained. This report demonstrates continued laboratory stability approximately eight months after the peak of the illness.

Major Findings

Erythrocyte Sedimentation Rate (ESR)

Result

4 mm/hr

Reference Range:

0–30 mm/hr

Interpretation

ESR remained well within the normal range and improved further compared with previous measurements.

Trend:

October 2021 (Peak): 71 mm/hr
December 2021: 15 mm/hr
January 2022: 6 mm/hr
February 2022: 13 mm/hr
March 2022: 16 mm/hr
April 2022: 8 mm/hr
June 2022: 4 mm/hr

This is one of the lowest ESR values recorded since recovery from the inflammatory illness and provides strong evidence of sustained remission.

C-Reactive Protein (CRP)

Result

2 mg/L

Reference Range:

0–10 mg/L

Interpretation

CRP remained comfortably within the normal range.

Trend:

October 2021 (Peak): 32 mg/L
December 2021: 2 mg/L
January 2022: 4 mg/L
February 2022: 1 mg/L
March 2022: 3 mg/L
April 2022: 2 mg/L
June 2022: 2 mg/L

The consistently normal CRP values over several months indicate continued absence of active systemic inflammation.

Overall Interpretation

This focused laboratory evaluation demonstrates continued remission of the systemic inflammatory illness. Both ESR and CRP remained within normal limits, with ESR decreasing to only 4 mm/hr and CRP remaining stable at 2 mg/L. The sustained normalization of both inflammatory markers over multiple consecutive evaluations provides strong objective evidence that the inflammatory process documented in late 2021 remained well controlled throughout the first half of 2022.

Longitudinal Significance

This report contributes to:

ESR Trend Table
CRP Trend Table
Systemic Inflammatory Illness Timeline
Rheumatology Consultation Summary
Medical History Timeline

It documents sustained inflammatory remission approximately eight months after the peak of illness.

Clinical Importance

⭐⭐⭐⭐ Sustained Recovery Confirmed

Although this report contains only two laboratory values, it is clinically significant because it confirms that recovery from the inflammatory illness was not temporary. The continued normalization of both ESR and CRP demonstrates ongoing disease control.

Key Changes Since Previous Report

Compared with the previous inflammation follow-up:

ESR improved from 8 → 4 mm/hr, remaining well within the normal range.
CRP remained unchanged at 2 mg/L.
Both inflammatory markers continued to demonstrate stable remission.
No laboratory evidence of recurrent systemic inflammation.

Related Reports

August 31, 2021 – Initial Systemic Inflammatory Evaluation
September 7, 2021 – Inflammation Monitoring Evaluation
October 13, 2021 – Peak Systemic Inflammatory Illness Evaluation
December 15, 2021 – Recovery Evaluation
January 12, 2022 – Continued Recovery Evaluation
February 9, 2022 – Autoimmune Evaluation
March 7, 2022 – Sjögren’s Antibody Evaluation
ESR Trend Table
CRP Trend Table
Rheumatology Consultation Summary
Medical History Timeline

Navigation

Previous Report: March 7, 2022 – Rheumatology Follow-up / Autoimmune Evaluation
Next Report: Subsequent 2022 Laboratory Evaluation
Return to Laboratory Library
Return to Health Inventory

Observation

This report marks an important milestone in the recovery phase of your health journey. By June 2022, the laboratory evidence showed that the dramatic inflammatory episode of 2021 had not only resolved but had remained in remission for several months.

The long-term trend is particularly striking:

Date	ESR	CRP
October 2021 (Peak)	71	32
December 2021	15	2
January 2022	6	4
February 2022	13	1
March 2022	16	3
April 2022	8	2
June 2022	4	2

This sequence tells a compelling story: after the severe inflammatory crisis of late 2021, your inflammatory markers steadily returned to and remained within normal ranges. By June 2022, the objective laboratory evidence strongly supported stable remission, making this report an important endpoint in the recovery phase of your Health Inventory.